Navigation Links
EXAMINE-Studie zur kardiovaskulären Sicherheit von Alogliptin erreicht primären Endpunkt: keine Erhöhung des kardiovaskulären Risikos bei Risikopatienten mit Typ-2 Diabetes
Date:9/11/2013

12,5 mg bzw. 25 mg zugelassen. Bei Patienten mit einer moderaten Einschränkung der Nierenfunktion (Creatinin-Clearance [CrCl] > 30 bis < 50 ml/min) beträgt die Dosis Alogliptin einmalig 12,5 mg pro Tag, und bei Patienten mit schwerer Einschränkung der Nierenfunktion (CrCl > 15 bis < 30 ml/min) und solchen mit Nierenerkrankungen im Endstadium (ESRD) (CrCl < 15 ml/min oder mit Hämodialysebedarf) beträgt die Dosis Alogliptin einmalig 6,25 mg pro Tag.

Alogliptin ist in Europa derzeit noch nicht zugelassen. VIPIDIA (Alogliptin), VIPDOMET (Alogliptin und Metformin FDC) sowie INCRESYNC (Alogliptin und Pioglitazon FDC) werden gegenwärtig von der Europäischen Arzneimittel-Agentur (EMA) geprüft und wurden vom Committee for Medicinal Products for Human Use (CHMP) im Juli 2013 positiv bewertet. Alogliptin wurde auch zur Anwendung in China, Mexiko und Südkorea zugelassen, obgleich die Therapie auf diesen Märkten noch nicht erhältlich ist.

Die Wirksamkeit von Alogliptin wurde als Ergänzung zu Diät und Bewegung sowie als Zusatztherapie für andere Antidiabetika untersucht, darunter Metformin, Pioglitazon, Insulin und Sulfonylharnstoffe. In diesen Studien wurde Alogliptin als 25-mg-Tablette einmal täglich eingenommen und zeigte eine klinisch und statistisch signifikante Reduzierung des HbA1c mit einem guten Verträglichkeitsprofil und einer geringen Hypoglykämie-Rate im Vergleich zur aktiven Kontrolle oder Placebo. Studienergebnisse legten nahe, dass Alogliptin bei gemeinsamer Verabreichung mit Metformin oder Pioglitazon in einer jeweiligen Therapie mit freier Dosierung zu einer wesentlichen Verbesserung der Blutzuckerkontrolle führte.

Informationen zu Takeda Pharmaceutical Company Limited
Takeda ist in Osaka, Japan, ansässig und ist ein weltweit agierendes Unternehmen mit Schwerpunkt
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. American College of Chest Physicians (ACCP) und Simbionix arbeiten zusammen, um klinische Ausbildung und Patientensicherheit zu verbessern
2. Messe/Konferenz InnoPack Pharma legt den Fokus auf innovative Verpackungen für Compliance und Sicherheit
3. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
4. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
5. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
6. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
7. National Diabetes Volunteer Leadership Council (NDVLC) Urges FDA to Enforce Stringent Accuracy Standards for Blood Glucose Monitoring Systems
8. Clinilabs Sponsors The ADAs 2013 Step Out: Walk to Stop Diabetes
9. GSMA mHealth Grand Tour Highlights How Mobile Technology Could Help Prevent 5 Million People In The EU From Developing Diabetes
10. Elcelyx Therapeutics NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
11. Bio-Solutions Corp. Expanding in Booming Diabetes Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... LONDON , July 11, 2014 /PRNewswire/ ... of visitors to Safety & Health Expo ... by the move to London ... senior management attending exhibition.     ... (Photo: http://photos.prnewswire.com/prnh/20140711/696892-a ) ...
(Date:7/10/2014)... , 11. Juli 2014 /PRNewswire/ ... Kameras für die molekulare Bildgebung, einschließlich ... heute die CE-Zulassung für sein Navigator ... kann Dilon das Produkt jetzt europaweit ... den Großteil der europäischen Länder ausgedehnt ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
Breaking Medicine Technology:UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
(Date:7/11/2014)... (PRWEB) July 12, 2014 According ... the total market is expected to register a ... 2019. , Browse 71 market data tables and ... TOC on "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , ... report., http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides ...
(Date:7/11/2014)... Butler Mobility has recently updated the paint ... . Previously the two standard colors were beige and ... tone colors as standard colors at no additional charge! ... but will enhance the beauty of the stairway. Homeowners ... scheme or individual décor. , The new selection of standard ...
(Date:7/11/2014)... Thompson HealthDay Reporter THURSDAY, ... with HIV who was thought to be cured by immediate ... detectable levels of the AIDS-causing virus in her bloodstream, disappointed ... 4 years old, had remained virus-free even though she stopped ... had hoped her remission would open the door to a ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 As ... investigation, Bernstein Liebhard LLP has been closely monitoring ... Drug Administration’s (FDA) Obstetrics and Gynecology Devices ... to mitigate the cancer risks associated with the ... surgeries. According to a report published by Dow ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Datalogic brings ... in improving sanitation hospital wide. With their new ... spread of disease, like the devastating MRSA, which claimed ... Gryphon GD4400-HC 2D and the Gryphon GM4400-HC ... barcodes and can even read barcodes off of troublesome ...
Breaking Medicine News(10 mins):Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3
... cause of adult-onset blindness, experts note , TUESDAY, Sept. 25 ... vision checked if they have access to health care, as ... say. , However, minorities with diabetes or people living in ... when they know why it is important to do so. ...
... resonance imaging (fMRI) have found a new marker which ... to a study published in the October issue of ... potential functional, rather than structural, brain markerseparate from atrophythat ... patients, said the studys lead author, Jeffrey R. Petrella, ...
... BOTHELL, Wash., Sept. 25 Cardiac Science,Corporation ... in advanced cardiac monitoring,and defibrillation products, today ... other lay rescuers from the Pittsburgh school ... defibrillator,(AED). (Logo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGO ) ...
... for research to improve health and welfare of ... companion animals and wildlife, ... for individuals or groups to demonstrate love,for and help animals via ... about 120 animal health studies available,for sponsorship. Animal lovers are invited ...
... ... Program Oct. 1, MINNEAPOLIS and ST. PAUL, Minn., ... major health plans and,ClearWay Minnesota(SM) -- is launching a new program that ... who,want to stop smoking. The Minnesota Clinic Fax Referral Program begins,October 1, ...
... One of the ,100 Best Companies ... Consecutive Year, ABBOTT PARK, Ill., Sept. 25 After ... to change. Lucky for,her, it didn,t have to be her ... She has since had a second child and,continues to work ...
Cached Medicine News:Health News:Regular Eye Screens Spot Diabetic Vision Trouble 2Health News:Radiologists identify early brain marker of Alzheimer's disease 2Health News:Radiologists identify early brain marker of Alzheimer's disease 3Health News:Cardiac Science Applauds Mass AED Training of Pittsburgh Educators 2Health News:Cardiac Science Applauds Mass AED Training of Pittsburgh Educators 3Health News:Cardiac Science Applauds Mass AED Training of Pittsburgh Educators 4Health News:Morris Animal Foundation 2008 Sponsorship Guide Available, Details Current Animal Health Studies 2Health News:Morris Animal Foundation 2008 Sponsorship Guide Available, Details Current Animal Health Studies 3Health News:Health Organizations Join Forces Around Quit-Smoking Help 2Health News:Abbott Again Honored as Top Company for Working Moms 2Health News:Abbott Again Honored as Top Company for Working Moms 3
The Oscor PACE 101 H is an external single chamber cardiac demand pacemaker. The PACE 101 H feature an option for a atrial overdrive stimulation....
... pacing wire design offers reliable ... in the atrium and ventricle ... in one lead design. The ... ventricle are color-coded for easy ...
... proprietary quadripolar pacing wire design ... and sensing in the atrium ... bipolar wires in one lead ... atrium and ventricle are color-coded ...
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: